Trial design randomized 175 symptomatic oHCM patients (NYHA II–III; LVOT gradient ≥30 mm Hg rest or ≥50 mm Hg Valsalva) to titrated aficamten 5–20 mg or metoprolol 50–200 mg for 24 weeks. Across 16 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results